Status:
UNKNOWN
Naldebain for Control of Post-Cesarean Section Pain
Lead Sponsor:
E-DA Hospital
Conditions:
Post Operative Pain, Acute
Post Operative Pain, Chronic
Eligibility:
FEMALE
20+ years
Phase:
PHASE2
Brief Summary
Inadequate postoperative pain management can lead to physical and psychological distress in patients as well as impact surgical wound healing and increase the risk of developing postoperative delirium...
Detailed Description
Inadequate postoperative pain management can lead to physical and psychological distress in patients as well as impact surgical wound healing and increase the risk of developing postoperative delirium...
Eligibility Criteria
Inclusion
- Term primipara or multipara
Exclusion
- Severe pregnancy-induced complication (such as preeclampsia, eclampsia, poorly control pregnancy-induced hypertension and/or diabetes)
- High risk for postpartum hemorrhage
- Contraindications for neuraxial block
- Preterm (gestational age\< 36 week) delivery
- Emergency cesarean section
- After-office hour schedule
- History of substance abuse
- Known allergy to nalbuphine, benzyl benzoate or sesame oil
- Not willing to follow the assignment of treatment after randomization
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05187520
Start Date
September 1 2022
End Date
October 1 2023
Last Update
April 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
E-Da Hospital
Yanchao, Kaohsiung, Taiwan, 824